Adetayo Lawal For many of us, the golden years are a time to look forward toan opportunity to travel, spend time in the garden, play with grandchildren or finally perfect our golf swing
In adults with obesity or overweight with 1 weight-related comorbidity, along with diet and exercise, A well-studied safety profile: Pooled safety data from 3 weight-management clinical trials evaluating Wegovy 2.4 mg pen 1 6.8% of patients treated with Wegovy and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions 1 Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of patients treated with Wegovy vs 0.7% of patients treated with placebo 1 The most common adverse reactions leading to discontinuation were: Nausea (1.8% vs 0.2%) , vomiting (1.2% vs 0%) , and diarrhea (0.7% vs 0.1%) for Wegovy and placebo, respectively 2 *Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort
Understanding GLP-1 Drugs and Their Severe Side Effects Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that have revolutionized the treatment of Type 2 diabetes and obesity
Since fibrosis is the most compelling predictor of outcomes, current and future therapies must focus on improving fibrosis by indirectly reducing pro-fibrotic inflammatory signaling or directly abrogating fibrosis
